Gilead Sciences, Inc. (GILD)
USD 90.69
(-2.27%)
USD 90.69
(-2.27%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 39.37 Billion USD | -6.16% |
| 2022 | 41.96 Billion USD | -10.51% |
| 2021 | 46.88 Billion USD | -6.57% |
| 2020 | 50.18 Billion USD | 28.76% |
| 2019 | 38.97 Billion USD | -7.51% |
| 2018 | 42.14 Billion USD | -15.35% |
| 2017 | 49.78 Billion USD | 32.35% |
| 2016 | 37.61 Billion USD | 14.94% |
| 2015 | 32.72 Billion USD | 73.66% |
| 2014 | 18.84 Billion USD | 75.27% |
| 2013 | 10.75 Billion USD | -8.01% |
| 2012 | 11.68 Billion USD | 12.01% |
| 2011 | 10.43 Billion USD | 90.75% |
| 2010 | 5.47 Billion USD | 71.32% |
| 2009 | 3.19 Billion USD | 11.42% |
| 2008 | 2.86 Billion USD | 28.27% |
| 2007 | 2.23 Billion USD | 0.78% |
| 2006 | 2.21 Billion USD | 204.26% |
| 2005 | 728.71 Million USD | 155.61% |
| 2004 | 285.09 Million USD | -48.33% |
| 2003 | 551.74 Million USD | -23.03% |
| 2002 | 716.84 Million USD | 109.39% |
| 2001 | 342.34 Million USD | 4.7% |
| 2000 | 326.97 Million USD | 134.39% |
| 1999 | 139.5 Million USD | 330.56% |
| 1998 | 32.4 Million USD | -6.9% |
| 1997 | 34.8 Million USD | 83.16% |
| 1996 | 19 Million USD | 25.0% |
| 1995 | 15.2 Million USD | 34.51% |
| 1994 | 11.3 Million USD | 0.0% |
| 1992 | 7.4 Million USD | 138.71% |
| 1991 | 3.1 Million USD | 34.78% |
| 1990 | 2.3 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 38.83 Billion USD | -1.37% |
| 2024 Q2 | 35.38 Billion USD | -8.89% |
| 2023 FY | 39.37 Billion USD | -6.16% |
| 2023 Q1 | 40.93 Billion USD | -2.44% |
| 2023 Q3 | 40.13 Billion USD | -2.7% |
| 2023 Q2 | 41.24 Billion USD | 0.75% |
| 2023 Q4 | 39.37 Billion USD | -1.88% |
| 2022 Q1 | 43.16 Billion USD | -7.94% |
| 2022 Q3 | 41.5 Billion USD | -2.71% |
| 2022 FY | 41.96 Billion USD | -10.51% |
| 2022 Q2 | 42.65 Billion USD | -1.18% |
| 2022 Q4 | 41.96 Billion USD | 1.11% |
| 2021 Q1 | 48.52 Billion USD | -3.3% |
| 2021 Q2 | 48.27 Billion USD | -0.52% |
| 2021 Q3 | 45.62 Billion USD | -5.48% |
| 2021 Q4 | 46.88 Billion USD | 2.76% |
| 2021 FY | 46.88 Billion USD | -6.57% |
| 2020 Q3 | 43.4 Billion USD | 14.86% |
| 2020 Q2 | 37.79 Billion USD | 0.61% |
| 2020 FY | 50.18 Billion USD | 28.76% |
| 2020 Q1 | 37.56 Billion USD | -3.63% |
| 2020 Q4 | 50.18 Billion USD | 15.62% |
| 2019 Q1 | 40.74 Billion USD | -3.31% |
| 2019 Q3 | 38.41 Billion USD | -5.06% |
| 2019 Q2 | 40.45 Billion USD | -0.7% |
| 2019 FY | 38.97 Billion USD | -7.51% |
| 2019 Q4 | 38.97 Billion USD | 1.48% |
| 2018 Q3 | 41.29 Billion USD | -5.33% |
| 2018 Q2 | 43.62 Billion USD | -2.48% |
| 2018 Q4 | 42.14 Billion USD | 2.04% |
| 2018 Q1 | 44.73 Billion USD | -10.15% |
| 2018 FY | 42.14 Billion USD | -15.35% |
| 2017 FY | 49.78 Billion USD | 32.35% |
| 2017 Q4 | 49.78 Billion USD | 26.32% |
| 2017 Q3 | 39.4 Billion USD | 6.02% |
| 2017 Q2 | 37.17 Billion USD | 1.05% |
| 2017 Q1 | 36.78 Billion USD | -2.21% |
| 2016 Q3 | 39.24 Billion USD | 15.9% |
| 2016 Q1 | 33.74 Billion USD | 3.12% |
| 2016 Q2 | 33.86 Billion USD | 0.35% |
| 2016 Q4 | 37.61 Billion USD | -4.17% |
| 2016 FY | 37.61 Billion USD | 14.94% |
| 2015 Q2 | 22.53 Billion USD | 8.68% |
| 2015 Q4 | 32.72 Billion USD | 0.1% |
| 2015 FY | 32.72 Billion USD | 73.66% |
| 2015 Q3 | 32.69 Billion USD | 45.09% |
| 2015 Q1 | 20.73 Billion USD | 10.02% |
| 2014 Q4 | 18.84 Billion USD | 25.79% |
| 2014 Q3 | 14.98 Billion USD | 1.38% |
| 2014 Q2 | 14.77 Billion USD | 2.79% |
| 2014 FY | 18.84 Billion USD | 75.27% |
| 2014 Q1 | 14.37 Billion USD | 33.7% |
| 2013 Q4 | 10.75 Billion USD | -4.64% |
| 2013 Q3 | 11.27 Billion USD | -0.04% |
| 2013 FY | 10.75 Billion USD | -8.01% |
| 2013 Q1 | 11.81 Billion USD | 1.11% |
| 2013 Q2 | 11.28 Billion USD | -4.55% |
| 2012 Q2 | 12.41 Billion USD | -1.33% |
| 2012 FY | 11.68 Billion USD | 12.01% |
| 2012 Q4 | 11.68 Billion USD | -4.3% |
| 2012 Q3 | 12.21 Billion USD | -1.65% |
| 2012 Q1 | 12.58 Billion USD | 20.61% |
| 2011 FY | 10.43 Billion USD | 90.75% |
| 2011 Q4 | 10.43 Billion USD | 62.89% |
| 2011 Q3 | 6.4 Billion USD | -1.17% |
| 2011 Q2 | 6.48 Billion USD | -4.83% |
| 2011 Q1 | 6.81 Billion USD | 24.52% |
| 2010 Q4 | 5.47 Billion USD | -1.9% |
| 2010 Q1 | 3.19 Billion USD | -0.0% |
| 2010 FY | 5.47 Billion USD | 71.32% |
| 2010 Q2 | 3.79 Billion USD | 18.9% |
| 2010 Q3 | 5.57 Billion USD | 46.89% |
| 2009 Q3 | 3.18 Billion USD | 3.63% |
| 2009 Q1 | 2.5 Billion USD | -6.38% |
| 2009 Q4 | 3.19 Billion USD | 0.27% |
| 2009 FY | 3.19 Billion USD | 11.42% |
| 2009 Q2 | 3.07 Billion USD | 22.8% |
| 2008 Q2 | 2.65 Billion USD | 8.71% |
| 2008 Q1 | 2.43 Billion USD | 9.18% |
| 2008 Q4 | 2.67 Billion USD | -0.28% |
| 2008 Q3 | 2.68 Billion USD | 1.07% |
| 2008 FY | 2.86 Billion USD | 28.27% |
| 2007 FY | 2.23 Billion USD | 0.78% |
| 2007 Q3 | 2.17 Billion USD | -2.29% |
| 2007 Q1 | 2.17 Billion USD | -1.91% |
| 2007 Q2 | 2.22 Billion USD | 2.31% |
| 2007 Q4 | 2.23 Billion USD | 2.77% |
| 2006 Q3 | 2 Billion USD | 0.94% |
| 2006 Q2 | 1.98 Billion USD | 210.58% |
| 2006 Q4 | 2.21 Billion USD | 10.84% |
| 2006 Q1 | 638.07 Million USD | -12.44% |
| 2006 FY | 2.21 Billion USD | 204.26% |
| 2005 FY | 728.71 Million USD | 155.61% |
| 2005 Q4 | 728.71 Million USD | 141.44% |
| 2005 Q3 | 301.82 Million USD | 1.94% |
| 2005 Q2 | 296.08 Million USD | -3.25% |
| 2005 Q1 | 306.01 Million USD | 7.34% |
| 2004 Q3 | 590.4 Million USD | 9.07% |
| 2004 Q2 | 541.3 Million USD | -0.39% |
| 2004 Q1 | 543.42 Million USD | -1.51% |
| 2004 FY | 285.09 Million USD | -48.33% |
| 2004 Q4 | 285.09 Million USD | -51.71% |
| 2003 FY | 551.74 Million USD | -23.03% |
| 2003 Q4 | 551.74 Million USD | -26.41% |
| 2003 Q3 | 749.8 Million USD | 0.26% |
| 2003 Q2 | 747.85 Million USD | 0.85% |
| 2003 Q1 | 741.58 Million USD | 3.45% |
| 2002 Q1 | 330.79 Million USD | -3.38% |
| 2002 Q4 | 716.84 Million USD | 102.84% |
| 2002 Q3 | 353.39 Million USD | 3.96% |
| 2002 Q2 | 339.93 Million USD | 2.76% |
| 2002 FY | 716.84 Million USD | 109.39% |
| 2001 Q3 | 334.79 Million USD | 3.89% |
| 2001 Q1 | 323.2 Million USD | -1.15% |
| 2001 FY | 342.34 Million USD | 4.7% |
| 2001 Q4 | 342.34 Million USD | 2.26% |
| 2001 Q2 | 322.24 Million USD | -0.3% |
| 2000 Q4 | 326.97 Million USD | 446.64% |
| 2000 Q2 | 134.33 Million USD | 0.79% |
| 2000 Q1 | 133.27 Million USD | -4.46% |
| 2000 FY | 326.97 Million USD | 134.39% |
| 2000 Q3 | 59.81 Million USD | -55.47% |
| 1999 Q3 | 149.4 Million USD | 449.26% |
| 1999 Q2 | 27.2 Million USD | -8.42% |
| 1999 Q4 | 139.5 Million USD | -6.63% |
| 1999 Q1 | 29.7 Million USD | -8.33% |
| 1999 FY | 139.5 Million USD | 330.56% |
| 1998 Q3 | 32 Million USD | -2.44% |
| 1998 Q2 | 32.8 Million USD | -13.68% |
| 1998 FY | 32.4 Million USD | -6.9% |
| 1998 Q4 | 32.4 Million USD | 1.25% |
| 1998 Q1 | 38 Million USD | 9.2% |
| 1997 Q2 | 23.4 Million USD | -13.65% |
| 1997 Q1 | 27.1 Million USD | 42.63% |
| 1997 FY | 34.8 Million USD | 83.16% |
| 1997 Q3 | 22.4 Million USD | -4.27% |
| 1997 Q4 | 34.8 Million USD | 55.36% |
| 1996 Q3 | 17.5 Million USD | 4.79% |
| 1996 Q4 | 19 Million USD | 8.57% |
| 1996 Q2 | 16.7 Million USD | -5.65% |
| 1996 Q1 | 17.7 Million USD | 0.0% |
| 1996 FY | 19 Million USD | 25.0% |
| 1995 Q3 | 15.2 Million USD | 6.29% |
| 1995 Q1 | 16.3 Million USD | -1.81% |
| 1995 Q2 | 14.3 Million USD | -12.27% |
| 1995 FY | 15.2 Million USD | 34.51% |
| 1994 Q1 | 11.3 Million USD | 7.62% |
| 1994 FY | 11.3 Million USD | 0.0% |
| 1994 Q4 | 16.6 Million USD | -3.49% |
| 1994 Q3 | 17.2 Million USD | 15.44% |
| 1994 Q2 | 14.9 Million USD | 31.86% |
| 1993 Q1 | 7.4 Million USD | 21.31% |
| 1993 Q2 | 6.4 Million USD | -13.51% |
| 1993 Q3 | 10.2 Million USD | 59.38% |
| 1993 Q4 | 10.5 Million USD | 2.94% |
| 1992 Q1 | 3.1 Million USD | 0.0% |
| 1992 Q3 | 5.5 Million USD | 111.54% |
| 1992 FY | 7.4 Million USD | 138.71% |
| 1992 Q4 | 6.1 Million USD | 10.91% |
| 1992 Q2 | 2.6 Million USD | -16.13% |
| 1991 Q1 | 2.3 Million USD | 0.0% |
| 1991 FY | 3.1 Million USD | 34.78% |
| 1990 FY | 2.3 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Amgen Inc. | 90.92 Billion USD | 56.693% |
| AstraZeneca PLC | 61.95 Billion USD | 36.442% |
| Biogen Inc. | 12.04 Billion USD | -226.897% |
| MIRA Pharmaceuticals, Inc. | 558.09 Thousand USD | -7055304.347% |
| Scilex Holding Company | 274.24 Million USD | -14257.86% |
| Scilex Holding Company | 274.24 Million USD | -14257.86% |